Schultz 1990.

Methods	Design: randomized controlled trial Generation of allocation sequence: unclear Allocation concealment: medication supplied to each trial centre in identical coded boxes Blinding: outcomes assessor Inclusion of randomized participants in the analysis: 87% (63/467 participants not analysed (for primary outcome))
Participants	Number: 467 enrolled (aged 2 months to 75 years, mean age 22.1 years; 297 males, 170 females) Inclusion criteria: clinical diagnosis of scabies Exclusion criteria: pregnancy; breastfeeding; treatment with ectoparasiticide within previous 3 weeks; renal impairment; hepatic impairment; known allergy to permethrin or lindane
Interventions	1. 5% permethrin cream applied to entire body below ears, single application (234 participants) 2. 1% lindane lotion applied from neck down, single application (233 participants)
Outcomes	1. Number of participants clinically cured at 28 +/‐ 7 days (defined as all original lesions healed and no new lesions) 2. Number of participants with persistence of itch 3. Adverse events Not included in this review: 4. Number of participants clinically cured at 14 +/‐ 3 days 5. Number of microbiologically confirmed cases clinically cured
Notes	Location: USA and Mexico (4 sexually transmitted diseases clinics, 2 dermatology clinics, and 2 family practice clinics, 1 of which was in Mexico and all others in USA) Date: not stated Personal contacts of 85% of participants provided with 1% lindane for their use Study supported in part by a grant from Burroughs Wellcome (manufacturers of permethrin) who also provided statistical assistance